Loading
Curium
Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.
Overview
Curium is a Paris-based private radiopharmaceutical group, one of the largest in nuclear medicine, supplying SPECT and PET isotopes and generators and developing 177Lu-PSMA-I&T as a competitor to Pluvicto in prostate cancer. Its ECLIPSE phase 3 trial of 177Lu-PSMA-I&T met its radiographic progression-free survival endpoint in taxane-naive metastatic castration-resistant prostate cancer, a Japanese registrational trial with PeptiDream and PDRadiopharma enrolled its first patient in February 2026, and the regulatory submission plan is under discussion with the FDA. In September 2026 the FDA approved Bexlutry, Curium's lutetium-177 dotatate, for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours. On 3 August 2026 Curium agreed to acquire Lantheus for 102.50 dollars a share in cash plus contingent value rights of up to 12 dollars a share, a total of up to about 8.0 billion dollars; the US Federal Trade Commission asked for more information on 21 October 2026, and the companies expect to close in the first half of 2027. OnCo links it to DOTATATE imaging agents, samarium-153 lexidronam, radionuclide generators and the therapeutic isotope supply chain. Whether a second lutetium PSMA agent can differentiate on supply and price rather than efficacy is the open question. The manufacturing cost of radioactive medicines is the bottleneck it bears on.
Headquarters
Paris, FR
Scorecard
All companies#96of 1520 companies, score 52
- approved products +18
- phase 3 +3
- targets +4
- modalities +4
- regions +3
- 24-month regulatory events +2
- registry trials +18
3 approved, 1 in phase 3, 0 earlier, 2 targets, 77 registry studies. Formula on the scorecards page.
Manufacturing
Capacity map- Curium Petten Petten, NLRadioisotope production, Radiopharmaceutical manufacturing
Website
Products
4Phase 3Radioligand therapy (beta)
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
ApprovedPET imaging agent
Piflufolastat F-18 / Pylarify TruVu · Pylarify
Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026.
ApprovedPET radiotracer (somatostatin receptor ligand)
Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
ApprovedBone-seeking therapeutic radiopharmaceutical (beta emitter)
Samarium-153 lexidronam · Quadramet
Quadramet (samarium-153 lexidronam) is a radioactive bone-seeking injection that lodges in bone metastases and irradiates them from inside, approved in 1997 to relieve pain from prostate, breast and other cancers spread to bone. Most patients get relief within one to two weeks, but marrow suppression follows at three to five weeks, and radium-223 and PSMA radioligands have largely replaced it.
Notes
- Checked 29 October 2026. Lantheus deal terms are from the joint release filed by Lantheus with the SEC on 3 August 2026; the FTC second request and the first-half 2027 closing expectation are from Lantheus's 8-K of 22 October 2026. The deal had not closed at the time of checking. Bexlutry approval is from Curium's release dated 14 September 2026. Curium also announced the acquisition of Abscint, a PET radiodiagnostics company, in August 2026; its terms were not checked.
Connected
16Similar pages
- CompanyEckert & Ziegler
Shares Radionuclide generators and cold kits, Radiopharmacy and cyclotron networks, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- CompanyIRE (Institut national des Radioéléments)
Shares Radionuclide generators and cold kits, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanyANSTO (Australian Nuclear Science and Technology Organisation)
Shares Radiopharmacy and cyclotron networks, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- TechnologyPET tracer manufacturing and distribution
Shares Radionuclide generators and cold kits, Lantheus, Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- TrialStudy of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Shares Piflufolastat F-18 / Pylarify TruVu, Lantheus, Prostate cancer.
- TrialStudy of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares Piflufolastat F-18 / Pylarify TruVu, Lantheus, Prostate cancer.
- CompanyPETNET Solutions (Siemens Healthineers)
Shares Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyCardinal Health Nuclear & Precision Health Solutions
Shares Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
cancers
fronts
technologies
Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)Radionuclide generators and cold kitsRadiopharmaceutical GMP and releasing a drug that decaysRadiopharmacy and cyclotron networksResearch reactors for medical isotopes (Mo-99, Lu-177, I-131)Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)
drugs
Phase 3Radioligand therapy (beta)
ApprovedPET radiotracer (somatostatin receptor ligand)
Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet
ApprovedPET imaging agent
Piflufolastat F-18 / Pylarify TruVu · Pylarify
ApprovedBone-seeking therapeutic radiopharmaceutical (beta emitter)
Samarium-153 lexidronam · Quadramet
companies
trials
bottlenecks
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
curiumpharma.com · 2
A source that has moved or gone is reported by the weekly link check. /audit/